New eye drop combo tested for safety in healthy people
NCT ID NCT06352541
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether PRO-232 eye drops, which combine an antibiotic (moxifloxacin) and a steroid (dexamethasone), are safe and tolerable for healthy adults. Twenty-eight volunteers received either the active drops or a placebo. Researchers monitored for unexpected side effects, changes in eye pressure, and stinging. The study is complete, but results are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1% ophthalmic solution
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigacion e Innovacion en Medicina Traslacional
Mexico City, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Which medical adhesive stays put longest without itching? a head-to-head test in healthy women.
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- New eye drop aims to tame ocular pain in early trial
- Could a formula closer to breast milk boost baby development?
- Could a daily probiotic help you feel fuller and eat less?